Article
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.
Cancer immunology research - 1 Jul 2017
Frazao Alexandra, Colombo Marina, Fourmentraux-Neves Emmanuelle, Messaoudene Meriem, Rusakiewicz Sylvie, Zitvogel Laurence, Vivier Eric, Vély Frédéric, Faure Florence, Dréno Brigitte, Benlalam Houssem, Bouquet Fanny, Savina Ariel, Pasmant Eric, Toubert Antoine, Avril Marie-Françoise, Caignard Anne
Abstract excerpt
Over 60% of human melanoma tumors bear a mutation in the BRAF gene. The most frequent mutation is a substitution at codon 600 (V600E), leading to a constitutively active BRAF and overactivation of the MAPK pathway. Patients harboring mutated BRAF respond to kinase inhibitors such as vemurafenib. However, these responses are transient, and relapses are frequent. Melanoma cells are efficiently lysed by activated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.